U.S. flag

An official website of the United States government

NM_007294.4(BRCA1):c.594_597delTGTG AND Hereditary cancer-predisposing syndrome

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Mar 7, 2019
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001024704.11

Allele description [Variation Report for NM_007294.4(BRCA1):c.594_597delTGTG]

NM_007294.4(BRCA1):c.594_597delTGTG

Gene:
BRCA1:BRCA1 DNA repair associated [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
17q21.31
Genomic location:
Preferred name:
NM_007294.4(BRCA1):c.594_597delTGTG
HGVS:
  • NC_000017.11:g.43095920_43095923del
  • NG_005905.2:g.122062_122065del
  • NM_007294.4:c.594_597delTGTGMANE SELECT
  • LRG_292t1:c.594_597del
  • LRG_292:g.122062_122065del
  • NC_000017.10:g.41247937_41247940del
  • NM_007294.3:c.594_597delTGTG
Links:
OMIM: 113705.0041; dbSNP: rs797045175
NCBI 1000 Genomes Browser:
rs797045175
Molecular consequence:
  • NM_007294.4:c.594_597delTGTG - splice acceptor variant - [Sequence Ontology: SO:0001574]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001186772Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Likely pathogenic
(Mar 7, 2019)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium.

Colombo M, Blok MJ, Whiley P, Santamariña M, Gutiérrez-Enríquez S, Romero A, Garre P, Becker A, Smith LD, De Vecchi G, Brandão RD, Tserpelis D, Brown M, Blanco A, Bonache S, Menéndez M, Houdayer C, Foglia C, Fackenthal JD, Baralle D, Wappenschmidt B; kConFaB Investigators., et al.

Hum Mol Genet. 2014 Jul 15;23(14):3666-80. doi: 10.1093/hmg/ddu075. Epub 2014 Feb 25.

PubMed [citation]
PMID:
24569164

Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.

Sawyer SL, Tian L, Kähkönen M, Schwartzentruber J, Kircher M; University of Washington Centre for Mendelian Genomics.; FORGE Canada Consortium., Majewski J, Dyment DA, Innes AM, Boycott KM, Moreau LA, Moilanen JS, Greenberg RA.

Cancer Discov. 2015 Feb;5(2):135-42. doi: 10.1158/2159-8290.CD-14-1156. Epub 2014 Dec 3.

PubMed [citation]
PMID:
25472942
PMCID:
PMC4320660

Details of each submission

From Ambry Genetics, SCV001186772.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

The c.594_597delTGTG variant, located in coding exon 8 of the BRCA1 gene, results from a deletion of 4 nucleotides at nucleotide positions 594 to 597, causing a translational frameshift with a predicted alternate stop codon (p.S198Rfs*35). This alteration was identified in a compound heterozygous state with another pathogenic BRCA1 alteration in a patient with features that were consistent with Fanconi Anemia including increased chromosome breakage upon DNA damage. Cells from this patient had numerous defects including reduced BRCA1 and RAD51 foci formation and ultrasensitivity to PARP inhibitors. These defects were rescued by a partial BRCA1 transgene to a level comparable to a sibling whose cells had only one BRCA1 alteration. This suggests that these defects are due specifically to BRCA1 deficiency (Sawyer SL et al. Cancer Discov, 2015 Feb;5:135-42). Alterations that result in premature protein truncation are typically deleterious in nature; however, this alteration occurs in one of the exons that is absent in a predominant, in-frame, naturally occurring isoform (Δ7_8, also known as Δ9,10 in the literature) and is likely to be spliced out in this normal isoform that produces a partially functional protein (Colombo M et al. Hum. Mol. Genet. 2014 Jul;23:3666-80; Whiley PJ et al. Clin. Chem. 2014 Feb;60:341-52), Therefore, the effect of this variant in a heterozygous state may be hypomorphic. Based on the majority of available evidence to date, this variant is likely to be pathogenic. However, because this variant is identified in one or more patients with Fanconi Anemia it may be hypomorphic and thus, carriers of this variant and their families may present with reduced risks, and not with the typical clinical characteristics of a high-risk pathogenic BRCA1 alteration. As risk estimates are unknown at this time, clinical correlation is advised.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 13, 2024